KalVista Pharmaceuticals Inc (STU:4XC1)
€ 8.8 -0.3 (-3.3%) Market Cap: 442.00 Mil Enterprise Value: 319.24 Mil PE Ratio: 0 PB Ratio: 3.05 GF Score: 30/100

Kalvista Pharmaceuticals Inc at Stifel Healthcare Conference Transcript

Nov 19, 2019 / 01:00PM GMT
Release Date Price: €10.4 (+5.05%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Well, thanks, everybody. My name is Paul Matteis. I'm a biotech analyst at Stifel. Happy to be hosting the KalVista CEO, Andy Crockett. I think Andy is going to kick it off with a presentation and a corporate update, and then maybe we'll have some time for Q&A at the end. So Andy, please, we'll switch places.

Thomas Andrew Crockett
KalVista Pharmaceuticals, Inc. - CEO & Director

Good morning, everyone. My name is Andy Crockett, Chief Executive of KalVista. Pleased to be with you here today. Just to remind everyone that this presentation does contain forward-looking statements, I'll refer you to the information on the slide.

Just as an overview of KalVista, we've been focused on discovery and development of small molecule protease inhibitors since our inception. We're creating a portfolio of oral plasma kallikrein inhibitors to treat both hereditary angioedema as well as diabetic macular edema. Our lead

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot